Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
17 07 2020
Historique:
received: 02 06 2020
revised: 29 06 2020
accepted: 05 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 24 11 2020
Statut: epublish

Résumé

We aimed to study the association between occupational exposure to pesticides and chronic lymphocytic leukemia (CLL) in Spain. Occupational exposure to pesticides (four insecticides, four herbicides and two fungicides) was evaluated using a job-exposure matrix for the Spanish population (MatEmESp) among 302 CLL cases and 1567 population controls in five regions of Spain, 2010-2013. Cumulative exposure scores (CES) were obtained by summing across the exposed jobs the product of prevalence, intensity and duration of exposure to each active substance. Principal components analysis (PCA) and logistic regression models adjusted for age, sex, region, education and occupational exposure to solvents were used. Around 20% of controls and 29% of cases were exposed to one or more pesticides. Compared to non-exposed, subjects in the highest tertile (3rd tertile) of CES of insecticides, herbicides, fungicides were more likely to have CLL [OR (95% CI), P-trend; 2.10 (1.38; 3.19), 0.002; 1.77 (1.12; 2.80), 0.12; and 1.67 (1.06; 2.64), 0.10, respectively). Following PCA, the first component (PC1, explaining 70% of the variation) equally led by seven active substances (the insecticide pyrethrin, all herbicides, all fungicides) was associated with a 26% higher odds of having CLL for 1-standard deviation increase in PC1 (95% CI: 1.14 to 1.40). These results confirm previous associations between CLL and exposure to pesticides and provide additional evidence by application groups and active substance. However, more research is needed to disentangle independent effects of individual active substances.

Identifiants

pubmed: 32709095
pii: ijerph17145174
doi: 10.3390/ijerph17145174
pmc: PMC7400560
pii:
doi:

Substances chimiques

Pesticides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Am J Ind Med. 1998 Apr;33(4):409-17
pubmed: 9513649
PLoS One. 2014 Oct 22;9(10):e109332
pubmed: 25337994
Scand J Work Environ Health. 1996 Dec;22(6):401-3
pubmed: 9000306
Occup Environ Med. 2009 May;66(5):291-8
pubmed: 19017688
Neurotoxicology. 2009 Nov;30 Suppl 1:S17-31
pubmed: 19766671
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Occup Environ Med. 2013 Jul;70(7):464-70
pubmed: 23576671
Lancet Oncol. 2014 Aug;15(9):931-42
pubmed: 25030467
East Mediterr Health J. 2014 Jun 18;20(6):363-71
pubmed: 24960512
Toxicology. 2013 May 10;307:35-41
pubmed: 23380243
J Occup Med Toxicol. 2017 Nov 23;12:31
pubmed: 29201133
Occup Environ Med. 2007 Aug;64(8):562-8
pubmed: 17053019
Arch Environ Occup Health. 2016 Nov;71(6):317-329
pubmed: 26566973
Occup Environ Med. 1998 Oct;55(10):651-6
pubmed: 9930084
Occup Environ Med. 2015 Jun;72(6):435-41
pubmed: 25694496
Occup Environ Med. 2000 Feb;57(2):126-32
pubmed: 10711281
Br J Haematol. 2010 Mar;148(5):739-53
pubmed: 19958356
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):41-51
pubmed: 25174025
Occup Environ Med. 2013 Feb;70(2):91-8
pubmed: 23117219
Ann Epidemiol. 2015 Nov;25(11):803-10
pubmed: 26365305
J Expo Sci Environ Epidemiol. 2011 Mar-Apr;21(2):212-21
pubmed: 20179749
Int J Epidemiol. 2019 Oct 1;48(5):1519-1535
pubmed: 30880337
Am J Ind Med. 2013 Oct;56(10):1226-38
pubmed: 23818037
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680

Auteurs

Yolanda Benavente (Y)

Cancer Epidemiology Research Programme, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.

Laura Costas (L)

Cancer Epidemiology Research Programme, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

Marta Maria Rodríguez-Suarez (MM)

Public Health Department, University of Oviedo, 33011 Oviedo, Spain.
Occupational Risk Prevention Service, Hospital Central University of Asturias, Public Health Service of the Principado of Asturias (SESPA), 33006 Oviedo, Spain.

Juan Alguacil (J)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, 21071 Huelva, Spain.

Miguel Santibáñez (M)

Faculty of Nursing, University of Cantabria-IDIVAL, 39008 Santander, Spain.

Javier Vila (J)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08903 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.

Claudia Robles (C)

Cancer Epidemiology Research Programme, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

Esther Alonso (E)

Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

Esmeralda de la Banda (E)

Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

Eva Gonzalez-Barca (E)

Hematology, Institut Català d' Oncologia (IDIBELL), Universitat de Barcelona, L' Hospitalet de Llobregat, 08908 Barcelona, Spain.

Trinidad Dierssen-Sotos (T)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Faculty of Medicine, University of Cantabria-IDIVAL, 39011 Santander, Spain.

Eva Gimeno Vazquez (E)

Hematology, Hospital del Mar, 08003 Barcelona, Spain.

Marta Aymerich (M)

Hematopathology Unit/Hemato-Oncology Department, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), 08001 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28001 Madrid, Spain.

Elias Campo (E)

Hematopathology Unit/Hemato-Oncology Department, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), 08001 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28001 Madrid, Spain.

José J Jiménez-Moleón (JJ)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, 18071 Granada, Spain.
Instituto de Investigación Biosanitaria de Granada, Servicio Andaluz de Salud, Universidad de Granada, 18012 Granada, Spain.

Rafael Marcos-Gragera (R)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), 17007 Girona, Spain.

Gemma Castaño-Vinyals (G)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08903 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), 08001 Barcelona, Spain.

Nuria Aragonés (N)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Department of Health of Madrid, Epidemiology Section, Public Health Division, 28035 Madrid, Spain.

Marina Pollan (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
National Center for Epidemiology, Carlos III Institute of Health, 28001 Madrid, Spain.
Instituto de Investigación Sanitaria (IIS) de Hierro, 28220 Majadahonda, Spain.

Silvia de Sanjose (S)

Cancer Epidemiology Research Programme, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
Sexual and Reproductive Health, PATH, Seattle, WA 98121, USA.

Manolis Kogevinas (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
ISGlobal, 08903 Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), 08001 Barcelona, Spain.

Adonina Tardón (A)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.
IUOPA Medicine Department, University of Oviedo, 33003 Oviedo, Spain.
Institute of Health Research of the Principality of Asturias-Foundation for Biosanitary Research of Asturias (ISPA-FINBA), 33003 Oviedo, Spain.

Delphine Casabonne (D)

Cancer Epidemiology Research Programme, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28001 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH